Author

John K. Lee

University of California, Los AngelesORCID 0000-0002-6570-2180Unclaimed ORCID profile · follow to get notified of new preprints

Additional preprints under this name without ORCID

John K. Lee1 paper

Biology Disciplines

Click to filter author papers

Cancer Biology· 4 Bioengineering· 2 Synthetic Biology· 1

Signature Assays, Organisms & Methods

Click to filter · or open tag

Approach:experimental assay· 6 Organism:human· 5 Research Focus:drug response / drug discovery· 4 Assay:bulk RNA-seq· 3 Assay:proteomics· 3 Research Focus:cancer & tumor microenvironment· 2 Research Focus:cell type annotation· 2 Organism:mouse· 2

Frequent Co-Authors

Vipul BhatiaiD· 4 shared Michael C. HaffneriD· 3 shared Peter S. NelsoniD· 3 shared Colm M. MorrisseyiD· 2 shared Jun IshiharaiD· 2 shared Kai SongiD· 2 shared Saul J. PricemaniD· 2 shared Thomas G. GraeberiD· 2 shared

Activity by Year

2024-2026 · peak 5/yr

Co-Author Collaboration Network

10 top collaborators · 23 mutual co-author links

Click any collaborator node to inspect or filter shared papers

Focal author (center)Selected co-authorORCID co-authorUnlinked name

Curved chords = mutual co-authorship

4 shared papersCancer Biology

Vipul BhatiaORCID

Mutual co-authors in cluster

Author profile →

7 papers

Recent·Most cited

Genotoxic antibody-drug conjugates combined with Bcl-xL inhibitors enhance therapeutic efficacy in metastatic castration-resistant prostate cancer

Galina Semenova, Sander B. Frank, Ruth F. Dumpit, Wanting Han, Ilsa M. Coleman, Roman Gulati, Canan D. Dirican, Tarana Arman, Jessica Maruwan, Colm M. Morrissey, Michael C. Haffner, Peter S. Nelson, John K. Lee

Journal of Clinical Investigation · Jun 23, 2026Peer-reviewedCancer Biology

Armoring STEAP1 CAR T cells with IL-18 potentiates antitumor activity in Ewing sarcoma

Vipul Bhatia, Annabelle Tsao, Truman Chong, Peter P. Challita, Keke Liang, Erolcan Sayar, Jiaoti Huang, Elizabeth R. Lawlor, Michael C. Haffner, Behnam Nabet, John K. Lee

This study shows that IL-18-armored STEAP1 CAR T cells effectively treat Ewing sarcoma with reduced dose and improved efficacy.

bioRxiv · Dec 11, 2025 · PreprintCancer Biology

Collagen-binding IL-12 expressing STEAP1 CAR-T cells reduce toxicity and eradicate mouse prostate cancer in combination with checkpoint inhibitors

Koichi Sasaki, Vipul Bhatia, Yuta Asano, Jakob Bakhtiari, Pooja Kaur, Chuyi Wang, Takumi Matsuo, Olivier Dubois, Po-Chuan Chiu, Donny Gun, Charanjit Singh, Ioanna Panagi, Laurine Noblecourt, Maria Nikolaidi, Truman Chong, , Jun Ishihara

Nature Biomedical Engineering · Oct 23, 2025Peer-reviewedBioengineering

Targeting the ITGA3B1 Complex with A Novel Antibody-Drug Conjugate for Metastatic Bladder Cancer

Hyeryeon Jung, Junghyeon Lee, Eunhee G. Kim, Jinsung Ahn, Michael C. Haffner, Peter S. Nelson, Kwang Pyo Kim, John K. Lee, Eugene C. Yi, Kristine M. Kim

The paper identifies ITGA3B1 as a therapeutic target for metastatic bladder cancer using a phenotypic screening strategy and develops an ADC targeting this integrin complex, showing antitumor efficacy in preclinical models.

bioRxiv · Apr 6, 2025 · PreprintSynthetic Biology

Solid tumor CAR T cells engineered with fusion proteins targeting PDL1 for localized IL-12 delivery

John Paul Murad, Lea Christian, Reginaldo Cruz Alves Rosa, Yuwei Ren, Eric Lee, Lupita S. Lopez, Anthony J. Park, Jason Yang, Candi Trac, Lauren N. Adkins, Wen‐Chung Chang, Catalina Martinez, Carl H. June, Stephen J. Forman, Jun Ishihara, , Saul J. Priceman

This study engineers CAR T cells with PDL1-IL12 fusion proteins to enhance anti-tumor responses in solid tumors by improving T cell function and reducing systemic inflammation.

bioRxiv · Apr 4, 2025 · PreprintBioengineering

Defined cellular reprogramming of androgen receptor-active prostate cancer to neuroendocrine prostate cancer

Shan Li, Kai Song, Huiyun Sun, Yong Tao, Arthur J. Y. Huang, Vipul Bhatia, Brian P. Hanratty, Radhika A. Patel, Henry W. Long, Colm M. Morrissey, Michael C. Haffner, Peter S. Nelson, Thomas G. Graeber, John K. Lee

This study reprograms AR-active prostate cancer to NEPC using ASCL1 and NeuroD1, revealing their role in silencing AR and altering chromatin structure.

bioRxiv · Feb 12, 2025 · PreprintCancer Biology

PGC-1a drives small cell neuroendocrine cancer progression towards an ASCL1-expressing subtype with increased mitochondrial capacity

Grigor Varuzhanyan, Chia‐Chun Chen, Jack Freeland, He Tian, Wendy Tran, Kai Song, Liang Wang, Donghui Cheng, Shili Xu, Gabriella DiBernardo, Favour N. Esedebe, Vipul Bhatia, Mingqi Han, Evan R. Abt, Jung Wook Park, , Owen N. Witte

Proceedings of the National Academy of Sciences · Nov 26, 2024Peer-reviewedCancer Biology